Anticoagulation Therapy Management: Policy 900.3207

Clinical Guidelines:

Initiation/Dosing: Anticoagulation selection for patients with non-valvular atrial fibrillation. See Guideline 900.5008

Initiation/Other: Direct Oral Anticoagulant Use for Venous Thromboembolism, see Protocol 900.5206

Transitioning: Warfarin transition (to or from rivaroxaban): See Guideline 900.5863

Surgery: Timing of Neuraxial Anesthesia and Anticoagulation: see Guideline 900.5681

Surgery: Periprocedural Management of Anticoagulation therapy: See Protocol 900.5011

Reversal: Reversal in bleeding patients or for emergent surgery: See Reversal Guideline 900.5010

Reversal: Idarucizumab is the available antidote for dabigatran.  Supply may be limited, call your inpatient pharmacist for information.

Do Not Crush: Bioavailability increases by 75% when the pellets are taken without the capsule shell.

• Micromedex
• CareNotes
• UpToDate
• Facts & Comparisons
• MedLinePlus (Patient Information)